When CMS Pulled Back MA Prior Authorization Transparency Rules, RCM Directors Lost More Than Data

“The June 2025 CMS decision did not change what Medicare Advantage plans can do to providers — it changed what providers can see.”

Executive Summary

On June 16, 2025, CMS announced it would not enforce the Medicare Advantage prior authorization transparency requirements it had finalized just fourteen months earlier. Specifically, CMS suspended the mandate that MA plan utilization management committees include a health equity expert and publish plan-level analyses of PA denial disparities by population. For RCM directors, this rollback is not merely a policy setback. It eliminated the only externally published benchmark providers could use to document discriminatory denial patterns, calibrate appeal strategy by plan, and apply competitive pressure in payer negotiations. With MA denial rates at a 5-year high of 7.7% in 2024, and plan-level rates ranging from 2% to 21%, the absence of transparency data shifts the entire accountability burden to providers. The strategic response is clear: build the internal tracking infrastructure that federal rules would have mandated externally.

Background / Regulatory Context

The Medicare Advantage prior authorization transparency framework had two distinct regulatory chapters — and understanding each is essential to understanding what providers lost.

Chapter One: CMS-4205-F and 42 CFR § 422.137 (April 2024)

In the Contract Year 2025 Medicare Advantage Final Rule (CMS-4205-F), finalized April 4, 2024, CMS established 42 CFR § 422.137. The rule required MA plan utilization management committees to include at least one member with health equity expertise, effective January 1, 2025. Committees were also required to conduct an annual health equity analysis of PA practices — examining denial, approval, and overturn rates disaggregated by population characteristics including dual eligibility status, low-income subsidy receipt, and disability — with results posted publicly in machine-readable format by July 1, 2025.

CMS grounded this rule in documented evidence: dually eligible MA beneficiaries face up to twice the prior authorization denial rate of non-dual enrollees despite submitting fewer requests. The regulation created the evidentiary infrastructure providers needed to identify outlier plans and substantiate appeals based on pattern-level data.

Chapter Two: CMS-4208-F Omission and the June 2025 Non-Enforcement Decision

Two events compounded the provider’s position — and they must be understood as distinct. First, CMS’s Contract Year 2026 Final Rule (CMS-4208-F, released April 4, 2025) declined to finalize the expanded health equity provisions proposed in CMS-4208-P — specifically service-level PA disparity reporting and baseline denial rate data collection. CMS indicated it may revisit these provisions in future rulemaking; no timeline was provided.

Second, on June 16, 2025, CMS announced it would not enforce the 42 CFR § 422.137 requirements already codified — the health equity committee expertise requirement that took effect January 1, 2025, and the plan-level health equity analysis originally due July 1, 2025. The April omission stopped new requirements from being created. The June announcement suspended enforcement of requirements that were already law.

What Remains in Force

MA organizations are still required to publish aggregate contract-level PA metrics — denial rates, approval rates, and turnaround times — in eight categories. The CMS-0057-F Interoperability and Prior Authorization Final Rule, which mandates FHIR-based API workflows for electronic PA submission and establishes a 7 calendar days standard and 72-hour expedited decision timelines, remains in force. These requirements provide a process framework; they do not restore the plan-level equity benchmarks that were suspended.

The Denial Mechanism

MA prior authorization denials operate through a two-layer structure: the plan’s internal clinical criteria layer, and CMS’s review and accountability layer. The transparency rollback weakened the second layer precisely when the first was generating its highest denial volume in five years.

In 2024, MA insurers denied 7.7% of approximately 53 million prior authorization requests — representing roughly 4.1 million denied PA requests (KFF, 2025). This rate has climbed from 5.7% in 2019 and 6.4% in 2023. The OIG’s 2022 analysis (OEI-09-18-00260) found that 13% of MA PA denials in its sample met Medicare coverage criteria — meaning plans were applying internal criteria stricter than traditional Medicare standards to generate medically unsupportable denials.

The variance across plans is striking. MedPAC data shows plan-level denial rates ranging from 2% to 21% among major MA insurers. Without plan-level published data, providers cannot identify which plans are outliers, cannot calibrate their appeal investment by plan, and cannot use peer benchmark data in contract negotiations.

The appeal opportunity is large and systematically underexploited: more than 80% of appealed MA PA denials are overturned — but only approximately 1% of denials are ever appealed (OIG OEI-09-18-00260; KFF 2024–2025). This gap is the operational leverage point. The suspension of transparency rules makes it harder to identify which plans and service lines justify systematic appeal pressure, because providers can no longer reference publicly available plan-level denial patterns to prioritize their appeal investments.

The rollback also removed a tool providers could have used in plan negotiations: a published, machine-readable health equity analysis creates a paper trail. Without it, systematic patterns of inappropriate denials remain invisible outside of individual claims data, which no single provider has at scale.

Top Denial Triggers

Submitting PA requests without a service-line denial baseline. With plan-level data suspended, RCM teams operating without internal tracking cannot identify which services and which plans generate the highest denial rates — so they cannot prepare clinical documentation proactively for high-risk service/plan combinations.
Inadequate documentation of medical necessity at the point of care. When plan-level denial patterns are opaque, providers cannot pre-identify the documentation thresholds specific plans apply. Generic clinical summaries are insufficient for plans using internal criteria stricter than Medicare coverage guidelines — the exact scenario OIG documented in 13% of its denial sample.
Failing to escalate denials that meet Medicare coverage criteria. OIG found that 13% of denials in its 2022 sample involved clinically appropriate care. RCM teams that do not systematically cross-check denials against traditional Medicare coverage policy miss recoverable revenue.
Underuse of the MA 5-level appeals ladder. Accepting denials from high-denying plans rather than pursuing the full appeals process leaves significant revenue on the table given overturn rates exceeding 80% at higher appeal levels (IRE and beyond).
Conflating IRE timelines with plan reconsideration deadlines. The IRE (MAXIMUS Federal Services) provides the critical break from plan self-review at Level 2; the 72-hour expedited pathway is available for urgent care but requires specific triggering language. Missing deadlines at any level forfeits appeal rights.
Misclassifying dual-eligible enrollees’ coverage pathway. Dually eligible patients enrolled in D-SNPs are subject to MA PA rules, not traditional Medicare FFS rules. RCM staff unfamiliar with D-SNP benefit structures may submit claims incorrectly or miss applicable PA requirements, generating avoidable denials.
Entering payer negotiations without plan-specific denial evidence. Without published plan-level denial and overturn data, contract renegotiations proceed without evidentiary support for demanding stronger PA terms, shorter authorization timelines, or clinical criteria alignment with Medicare policy. Providers who have not built internal tracking have no substitute.

Prevention Strategies

Build an internal PA denial registry segmented by plan, service line, and denial reason code. This is the operational substitute for the suspended plan-level data. Track denial rates, overturn rates, and average processing times internally to replicate at the practice level what CMS would have required plans to publish externally. Review monthly; use this data to set priority queues for appeals staff.
Develop a plan-specific denial pattern library. Using your internal registry, identify the services and clinical criteria most frequently denied by each contracted MA plan. Use this to flag high-risk PA submissions for documentation enhancement before submission — converting a reactive denial pattern into a proactive documentation protocol.
Create a standing letter-of-medical-necessity library tied to service categories. Pre-built templates aligned to Medicare coverage criteria for high-denial services (post-acute care, home health, DME, specialist referrals) reduce documentation variability and accelerate IRE escalation when plans uphold denials. Templates should be reviewed quarterly against published Medicare LCD/NCD updates.
Implement a systematic appeal triage protocol with mandatory escalation triggers. Every denial should be triaged against three criteria: Does it meet traditional Medicare coverage criteria? Is it above the ALJ amount-in-controversy threshold ($190 in 2025)? Is it from a plan with a documented high denial rate in your internal registry? Affirmative answers on any criterion trigger mandatory appeal initiation, not optional review.
Train billing staff on D-SNP-specific PA and billing workflows. With D-SNP enrollment at 5.5 million beneficiaries nationally and growing, staff who cannot identify D-SNP-enrolled patients and route them correctly through MA PA processes — rather than FFS workflows — generate systematic errors in PA submission and claims routing.
Leverage CMS-0057-F FHIR API workflows for electronic PA. The Interoperability and Prior Authorization Final Rule remains operative. Plans subject to CMS-0057-F must support FHIR-based electronic PA workflows; adopting these reduces processing lag, creates an electronic audit trail, and positions practices to hold plans accountable to the rule’s decision timeline requirements.
Enter payer contract negotiations with your internal denial data as evidentiary support. Without publicly available plan-level health equity analyses, your internal denial registry becomes your primary negotiating evidence. Bring plan-specific denial rates, overturn rates, and service-line patterns to renewal discussions. Frame substandard PA performance as a contract issue: excessive denials relative to Medicare coverage standards, unreasonable processing times, or systemic underperformance relative to peer plans.
Establish a dedicated expedited appeals routing protocol. The 72-hour IRE expedited pathway and Level 3 ALJ process require specific triggering documentation and strict timeline management. Designate a point person for expedited escalation decisions so denials involving active patient care do not expire past appeal windows during high-census periods.

FQHC-Specific Considerations

FQHCs occupy a particularly exposed position in this policy landscape. The populations the suspended transparency rules were designed to protect — dually eligible, low-income, disabled, and minority beneficiaries — are precisely the patient panels that define the FQHC mission. As of 2024, FQHCs serve nearly 34 million patients, the majority from low-income and publicly insured households (NACHC 2024 UDS). FQHCs added over 227,000 Medicare patients in 2024, a substantial proportion of whom are dually eligible. D-SNP enrollment growth is directly relevant: D-SNPs grew from 2.6 million enrollees in 2020 to 5.5 million in 2024. FQHCs serving D-SNP-enrolled patients are fully subject to MA PA processes — with no externally published benchmark for comparing a plan’s denial behavior to peers.

The loss of plan-level health equity analysis data eliminates a reference point FQHCs and community health advocates could have used to document disparate patterns in payer negotiations and state-level advocacy. This is a strategic loss, not merely a data inconvenience.

A critical data gap must be acknowledged: No published FQHC-specific MA prior authorization denial rate is currently available. This gap is itself a structural consequence of the transparency deficit the suspended rules were designed to address. Until plan-level data is published or FQHC-specific research emerges, revenue cycle teams at community health centers should assume their MA denial profile reflects the broader population-level patterns documented in OIG and KFF research. Build internal tracking accordingly. Do not cite FQHC-specific MA denial statistics where no verified source exists.

Cost report and operating margin implications: FQHCs carry an average operating margin of -2.4% in 2024. PA denials from MA plans compound financial pressure that community health centers have limited capacity to absorb. Under encounter-based PPS billing, unrecovered MA denials directly reduce net encounter revenue without a cost offset. Systematic appeals are not a discretionary activity at this margin level — they are a financial survival mechanism.

HRSA compliance interaction: There is no direct HRSA compliance requirement triggered by the MA transparency rollback. However, FQHCs should ensure that internal denial tracking and appeals protocols are reflected in operational compliance documentation to the extent that MA payment shortfalls affect service delivery obligations under the Health Center Program agreement.

Key Takeaway

The June 2025 CMS non-enforcement decision did not change what Medicare Advantage plans can do to providers — it changed what providers can see. The plan-level health equity data that 42 CFR § 422.137 would have required was never primarily a political accountability mechanism. It was an evidentiary resource that RCM directors could have used to benchmark performance, negotiate contracts, and appeal denials with precision. With that resource eliminated and the April 2025 final rule declining to create its successor, the accountability infrastructure must now be built internally. Revenue cycle teams that establish rigorous denial tracking by plan and service line, train staff on the full MA appeals ladder, and leverage their internal data as negotiating evidence will recover revenue. Less disciplined operations will surrender it. The 80%-plus overturn rate at appeal is not an anomaly — it reflects the documented gap between what MA plans deny and what Medicare covers. Closing that gap systematically, without the transparency data CMS suspended, is now the defining operational challenge in MA revenue cycle management.

Regulatory references: 42 CFR § 422.137; CMS-4205-F (CY2025 MA Final Rule, finalized April 4, 2024); CMS-4208-F (CY2026 MA Final Rule, April 2025); CMS-0057-F (Interoperability and Prior Authorization Final Rule); OIG Report OEI-09-18-00260 (April 2022); KFF Medicare Advantage Prior Authorization Data (2024–2025); MedPAC; NACHC 2024 UDS Early Takeaways; Georgetown/CHIR Medicare Policy Initiative (Ciannah Correa, June 2025).

Connected RCM: Insights and Overviews